{"id":"W4385667085","doi":"10.1097/01.hs9.0000971256.60488.02","title":"P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Ibrutinib; Medicine; Mantle cell lymphoma; Obinutuzumab; Internal medicine; Bendamustine; Regimen; Oncology; Adverse effect; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000665376,0.0003354619,0.0006880193,0.0003640346,0.0005899843,0.0006662809,0.0003764907,0.0007007752,0.001362154],"category_scores_gemma":[0.001163224,0.0001951407,0.000623446,0.0005027456,0.0002206566,0.0008051145,0.0004537632,0.0009578021,0.0005299458],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005372833,"about_ca_system_score_gemma":0.0002739248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001904969,"about_ca_topic_score_gemma":0.002350761,"domain_scores_codex":[0.999767,0.0000578229,0.00002162226,0.00006935467,0.0000337004,0.00005055056],"domain_scores_gemma":[0.999145,0.0001168131,0.0002731465,0.00007071288,0.00008359687,0.0003106951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0575142,0.002119606,0.8551853,0.0001925865,0.0008236272,0.002246186,0.0004117608,0.0006382453,0.006576051,0.00007515166,0.0056426,0.06857464],"study_design_scores_gemma":[0.001897187,0.01163393,0.9800895,0.00004655914,0.0005902615,0.001211717,0.000147705,0.0007385872,0.0006882778,0.0001070294,0.002816,0.00003323113],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955813,0.001209421,0.0001213741,0.0002019619,0.00003595019,0.00006060728,0.001872126,0.00001733043,0.0008998003],"genre_scores_gemma":[0.9941261,0.0003609877,0.0001365086,0.0002354462,0.0000723175,0.00007104033,0.004294971,0.000006649236,0.0006959832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001904969,"threshold_uncertainty_score":0.004556835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01498899969128477,"score_gpt":0.2636121938561011,"score_spread":0.2486231941648164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}